Gaby L. Danan is board qualified in Hepatology and Internal Medicine. He conducted experimental and clinical studies dealing with drug hepatotoxicity and drug-drug interactions. He joined the pharmaceutical industry in 1984 and was EU Qualified Person for Pharmacovigilance in Sanofi S.A. before his retirement in 2010. Together with Dr Christian Benichou he published in 1993 a causality assessment method for suspected Drug-Induced Liver Injury known as RUCAM.
From 1992 to 2009, he was a member of several CIOMS groups and ICH Expert Working Groups especially on Clinical Safety as EFPIA topic leader of E2B. He authored numerous papers and book chapters on definitions and methodology in Pharmacovigilance.